Intermittent hypoxic pretreatment exacerbates house dust mite-induced asthma airway inflammation

Hao Meng1, Dongxue Zhang2, Yifan Que1

  • 1Health Management Institute, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Medical School of Chinese PLA, Beijing, China.

Abstract

Insights

Intermittent hypoxic preconditioning (IHP) may worsen house dust mite-induced asthma by increasing airway inflammation and NF-κB activation, especially with high allergen doses.

Area of Science:

  • Pulmonary Medicine
  • Immunology
  • Environmental Health

Background:

  • Asthma is an inflammatory disorder where the role of hypoxia is not fully understood.
  • Hypoxia, a common environmental factor, may influence asthma development and progression.
  • The inflammatory microenvironment in asthma is a key area of research.

Purpose of the Study:

  • To investigate the impact of intermittent hypoxia preconditioning (IHP) on house dust mite (HDM)-induced asthma in a mouse model.
  • To determine the role of NF-κB signaling in hypoxia-exacerbated asthma.
  • To assess if allergen dose affects hypoxia's impact on asthma.

Main Methods:

  • Asthma was induced in mice using house dust mite (HDM) extracts over 23 days.
  • Mice were exposed to room air (RA) or intermittent hypoxia (IH), with some receiving IHP before hypoxia.
  • Airway inflammation markers, mucus secretion, inflammatory cell recruitment, and NF-κB expression were evaluated.

Main Results:

  • IHP significantly aggravated airway inflammation and hyperresponsiveness compared to RA and IH groups.
  • Increased inflammatory mediators and NF-κB expression were observed in the IHP group.
  • The exacerbating effect of hypoxia on asthma was more pronounced with high-dose allergen exposure.

Conclusions:

  • Intermittent hypoxic preconditioning (IHP) can exacerbate HDM-induced airway inflammation in asthma.
  • NF-κB signaling is implicated in the mechanism of hypoxia-induced asthma exacerbation.
  • High-dose allergen exposure amplifies the negative impact of hypoxia on asthma severity.

Related Concept Videos

Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
391
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
284
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
240